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Aims: Cancer cachexia is a syndrome which results in severe loss of muscle mass
and marked fatigue. Conditioned media from cachexia-inducing cancer cells triggers
metabolic dysfunction in skeletal muscle, including decreased mitochondrial respiration,
which may contribute to fatigue. We hypothesized that Lewis lung carcinoma conditioned
medium (LCM) would impair the mitochondrial electron transport chain (ETC) and increase
production of reactive oxygen species, ultimately leading to decreased mitochondrial
respiration. We incubated C2C12 myotubes with LCM for 30min, 2, 4, 24 or 48 h. We
measured protein content by western blot; oxidant production by 2′,7′-dichlorofluorescin
diacetate (DCF), 4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate (DAF), and
MitoSox; cytochrome c oxidase activity by oxidation of cytochrome c substrate; and
oxygen consumption rate (OCR) of intact myotubes by Seahorse XF Analyzer. Results:
LCM treatment for 2 or 24 h decreased basal OCR and ATP-related OCR, but did not alter
the content of mitochondrial complexes I, III, IV and V. LCM treatment caused a transient
rise in reactive oxygen species (ROS). In particular, mitochondrial superoxide (MitoSOX)
was elevated at 2 h. 4-Hydroxynonenal, a marker of oxidative stress, was elevated in
both cytosolic and mitochondrial fractions of cell lysates after LCM treatment. Conclusion:
These data show that lung cancer-conditioned media alters electron flow in the ETC and
increases mitochondrial ROS production, both of which may ultimately impair aerobic
metabolism and decrease muscle endurance.
Keywords: cachexia, mitochondria, oxidants, electron transport chain, skeletal muscle
INTRODUCTION
Cancer kills nearly 600,000 Americans annually, equating to
approximately 1500 deaths every day (Society, 2012). Fifty per-
cent of all cancer patients experience cachexia, a severe wasting
syndrome that includes loss of muscle mass, weakness and fatigue
(Tan and Fearon, 2008; Fearon et al., 2011). Cachexia is unrespon-
sive to nutritional interventions, and limits the response to cancer
treatments (Fearon et al., 2013). Eighty percent of patients with
advanced lung, prostate, colon, and pancreatic cancers present
with cachexia (Tisdale, 2009; Von Haehling et al., 2010; Fearon
et al., 2011; Johns et al., 2013). Although studies are ongoing,
we currently know that malignant tumors alter their surrounding
environment via tumor-derived and host-derived paracrine fac-
tors, which promote cachexia and may also lead to mitochondrial
dysfunction. Some recent studies found evidence of mitochon-
drial dysfunction in cachexia, which may contribute to muscle
pathology (Tan and Fearon, 2008; Constantinou et al., 2011;
Fearon et al., 2011; Julienne et al., 2012, 2014; Wang et al., 2012;
White et al., 2012; Dumas et al., 2013; Fontes-Oliveira et al., 2013;
Tzika et al., 2013).
Abbreviations: ETC, electron transport chain; LCM, Lewis lung carcinoma con-
ditioned medium; OCR, oxygen consumption rate; PAGE, polyacrylamide gel
electrophoresis; VDAC, voltage dependent anion channel.
Mitochondria are multi-functional organelles that provide a
majority of ATP to cells, are the major source of reactive oxy-
gen species (ROS), and participate in multiple signaling cascades,
including apoptosis. Reactive oxygen species play an important
role in maintenance and adaptation of skeletal muscle (Irrcher
et al., 2009; Merry et al., 2010; Dutka et al., 2012; Luo et al., 2013;
Michaelson et al., 2013; Prosser et al., 2013). At low concentra-
tions, ROS function in homeostatic signaling cascades, while at
high concentrations they cause damage by oxidizing DNA, pro-
teins, and lipids (Lee et al., 2012); in skeletal muscle, excessive
oxidant production affects skeletal muscle mass and function in
ways consistent with cachexia (Andrade et al., 1998, 2001; Reid
et al., 2005; Hardin et al., 2008; Gilliam et al., 2011).
In this study, we examined the effect of Lewis lung carcinoma
condition media (LCM) on mitochondrial function, protein con-
tent, and ROS production in C2C12 skeletal muscle myotubes.
C2C12s are an immortalized cell line of mouse skeletal mus-
cle that fuse and differentiate into myotubes under low-serum
conditions (Yaffe and Saxel, 1977). They are a useful model is
studying signaling pathways in skeletal muscle under controlled
conditions. We chose Lewis lung carcinoma as our cancer model
because it is known to induce cachexia and because lung cancer
accounts for 23% of all cancer deaths worldwide (Carbo et al.,
2004; Argiles et al., 2008; Jemal et al., 2011; Puppa et al., 2014).
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Then, we exposed C2C12 myotubes to LCM for 30min, 2, 4,
24, or 48 h. We hypothesized that LCM would impair mitochon-
drial respiration, increase ROS production, and lead to oxida-
tive stress. To test our hypothesis, we assessed the following in
myotubes: mitochondrial oxygen consumption, content of mito-
chondrial complexes, voltage-dependent anion channel (VDAC),
4-hydroxynonenal (4HNE), and uncoupling protein 3 (UCP3),
the activity of cytochrome c oxidase, and oxidant production via
DCF, DAF, and Mitosox.
MATERIALS AND METHODS
MYOTUBES
C2C12 myoblasts (American Type Culture Collection) were
plated at a density of 10,000 cells/cm2 in growth medium
[Dulbecco’s modified Eagle’s medium (DMEM) with 10%
fetal bovine serum, 1.6 g/L sodium bicarbonate, and 100U/ml
PenStrep (Invitrogen)] and cultured at 37◦C in 5% CO2. Cells
reached ∼90% confluence after 3 days, at which time cells were
serum restricted in differentiation media (DMEM as above with
2% horse serum replacing fetal bovine serum). After 4 days of
serum restriction, multinucleated myotubes were ready for treat-
ment. Fresh medium was added every 2 days (Moylan et al.,
2014).
LUNG CANCER CELLS
Lewis lung carcinoma cancer cells (LL/2: American Type Culture
Collection) were seeded at a density of 6000/cm2 in 100mm
cell culture plates in growth medium, as above. After 2 days,
additional growth media was added to each plate. LL/2 cells
are a heterogeneous mix of floating and adherent cells. After 4
days, we removed growth medium and harvested floating cells by
centrifugation at 500 × g, 5min. Pelleted cells and 10mL differ-
entiation media were added back to the adherent cells. After 2
days, we collected conditioned medium, removed cells and debris
by centrifugation (500 × g, 5min), and froze aliquots in liquid
nitrogen for later use. For treatments, we used a 1 in 4 dilution of
conditioned media mixed with fresh differentiation media.
WESTERN BLOT
C2C12 myotubes were homogenized in 2X protein loading
buffer (120mM Tris pH 7.5, 4% SDS, 200mM DTT, 20%
glycerol, 0.002% bromphenol blue). We separated proteins
in equal volumes of lysates by SDS-PAGE (4–15% Criterion,
BioRad) and determined relative total protein by scanning
(Odyssey Infrared Imaging, LI-COR) stained gels (Simply Blue,
Invitrogen). Fluorescence intensity data were used to normalize
total protein for equal loading. Equal amounts of protein were
separated by SDS-PAGE and transferred to PVDF membranes
for western blot using the Odyssey System (Moylan et al., 2014).
For preparation of mitochondrial and cytosolic fractions, mito-
chondria were isolated as in Lemire et al., and western blots were
performed as above (Lemire et al., 2008).
ANTIBODIES
Primary antibodies were rabbit anti-VDAC and rabbit anti-4
HNE (Abcam), mouse anti-Complex I NDUFA9, mouse anti-
Complex III, subunit core I, mouse anti-Complex IV, subunit
IV (Novex), and mouse anti-ATP synthase α (Mitosciences).
Secondary antibodies included anti-mouse IRDye 800CW and
anti-rabbit IRDye 800CW (LI-COR).
OXIDANT ASSAYS AND ANTIOXIDANT TREATMENTS
Tomeasure cytosolic oxidant activity, we aspirated off the cell cul-
ture media, replaced it with pre-warmed PBS supplemented with
glucose (D-PBS) and 2′,7′-dichlorofluorescein diacetate (DCFH-
DA 10μM, Molecular Probes). We incubated C2C12 myotubes
in DCFH-DA for 30min, 37◦C, 5% CO2. After incubation,
we washed the cells twice with D-PBS, and added fresh D-
PBS. To measure nitric oxide, we followed the same procedure
as above using DAF-FM diacetate (4-amino-5-methylamino-
2′,7′-difluorofluorescein diacetate) (DAF-FM 5μM, Molecular
Probes). We used a spectrofluorometer (Synergy H1, BioTek) to
measure fluorescence of the oxidized derivatives, DCF (excitation:
480 nm, emission 520 nm) and DAF-FM (excitation: 495 nm,
emission 515 nm), respectively. Antioxidant treatments included
either 100μM SS31, a mitochondrial-targeted antioxidant, or
5mmol N-Acetylcysteine, a general antioxidant (Cho et al., 2007;
Whiteman et al., 2008; Manczak et al., 2010; Powers et al., 2011).
Both were administered simultaneously with LCM treatment.
FLUORESCENCE MICROSCOPY
We incubated C2C12 myotubes with MitoSox (5μM, Molecular
Probes), a mitochondrial superoxide anion specific indicator, for
30min. Cells were rinsed twice with pre-warmed 1X PBS supple-
mented with glucose and sodium pyruvate. We captured live cell
fluorescence images (excitation: 510 nm, emission 580 nm) using
a CCD camera (CoolSNAP-ES, Roper Scientific Photometrics)
attached to a Nikon TE2000microscope with NIS Elements image
acquisition software (Nikon).
OXYGEN CONSUMPTION RATE
We cultured C2C12 myotubes as above in XFe24 Analyzer plates
(Seahorse Bioscience). Before running the assay, we replaced dif-
ferentiation media with Seahorse assay medium supplemented
with 10mM sodium pyruvate and 10mM glucose, and we
adjusted the pH to 7.4. Seahorse assay medium is non-buffered
for measuring proton production. Plates were equilibrated in this
medium for 1 h at 37◦C with no CO2. We used the same media
as vehicle for our injection compounds. The analyzer sequentially
injected the following compounds: oligomycin (1μM final con-
centration), which blocks ATP synthase and shows the OCR ded-
icated to ATP production; carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP: 4μM final concentration), which per-
meabilizes the inner mitochondrial membrane and shows maxi-
mal OCR; and rotenone (1μMfinal concentration), which blocks
complex I and shows NADH-driven OCR. There were 3–4 wells
per treatment group, and 4 plates in total. We measured OCR at
three time points during basal respiration and after each injection
using a Seahorse XFe24 Flux Analyzer (Seahorse Biosciences). We
normalized OCR measurements to VDAC content in each well
determined via western blot.
CYTOCHROME C OXIDASE ACTIVITY
We measured mitochondrial complex IV activity using a
Cytochrome Oxidase assay kit (Biovision) per manufacturer’s
protocol. Briefly, we lysed C2C12 myotubes by 3 freeze-thaw
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cycles in 20mM hypotonic potassium phosphate buffer pH 7.5
supplemented with protease and phosphatase inhibitor cock-
tails (Sigma). In a 96 well plate, we added Cytochrome c and
Cytochrome Oxidase Assay Buffer (Biovision) to 2μg total pro-
tein and recorded the decrease in optical density (OD) at 550 nm
over 45min using a spectrophotometer (Synergy H1, BioTek).
The decrease in optical density is proportional to an increase
in oxidized cytochrome c. We derived activity from the reac-
tion rate in the linear phase, i.e., cytochrome oxidase activity
(Units/mg) = [(OD1-OD2)/(t1-t2)]/(ε xmg protein), where ε
is the molar extinction coefficient of cytochrome c at 550 nm
(7.04mM−1cm−1) and one unit oxidizes one μmole reduced
cytochrome c per minute.
STATISTICS
Prism 5.0b (GraphPad Software) and SAS served as our statis-
tics software. We used t-test, One-Way ANOVA and post-hoc
Bonferroni test, or repeated measures ANOVA as appropriate.
Data are presented as mean ± SE. Statistical significance was
defined as p < 0.05.
RESULTS
PRE-TREATMENT WITH LCM DECREASES MITOCHONDRIAL
RESPIRATION
To assess how LCM affects mitochondrial function in skeletal
muscle, we examined C2C12 myotubes after 30min, 2, or 24 h
in LCM. LCM treatment altered respiration in a time-dependent
manner (Figure 1A). Western blots showed that VDAC content
is unaffected by LCM treatment; therefore, we normalized OCR
to VDAC content (Figure 1B). Thirty minutes of LCM treatment
did not affect electron transport chain (ETC) activity; however,
2 or 24 h of LCM treatment resulted in depressed basal respira-
tion (Figure 1C). The difference between basal respiration and
oligomycin-sensitive respiration represents the OCR dedicated
to ATP production. Compared to control myotubes, myotubes
exposed to 2 or 24 h of LCM had significantly less ATP-related
OCR (Figure 1D).
PROTEIN CONTENT OF MITOCHONDRIAL COMPLEXES IN C2C12
MYOTUBES TREATED WITH LCM
To test whether the decreased mitochondrial respiration in LCM-
treated myotubes was caused by changes in ETC complexes, we
measured their content by western blot. Each complex in the ETC
has multiple subunits, and we measured a representative subunit
for each complex as follows: mitochondrial complex I NDUFA9;
complex III subunit core I; complex IV subunit IV; and complex
V, subunit α. LCM treatment did not alter the content of any ETC
complex subunit measured (Figure 2).
EFFECT OF LCM TREATMENT ON CYTOCHROME C OXIDASE ACTIVITY
Cytochrome c oxidase is the last complex in the electron transport
chain. It transfers four electrons to molecular oxygen. A decrease
in cytochrome c absorbance indicates an increase in cytochrome
c oxidase activity. Cytochrome c oxidase activity in myotubes
treated with LCM for 2 h increased compared to control myotubes
(Figure 3). These results suggest that there is an early burst of
cytochrome c oxidase activity upon exposure to LCM.
FIGURE 1 | Oxygen consumption rate (OCR) in C2C12 myotubes.
Eleven total OCR measurements were taken over 2 h: 3 basal respiration, 3
Oligomycin-sensitive respiration, 3 maximal respiratory capacity, and 2
non-mitochondrial respiration. The x-axis in (A) describes the measurement
number. (A) OCR normalized to VDAC content presented at % basal control
in control myotubes vs. myotubes treated for 30min, 2 or 24 h with LCM
(n = 12, ∗P < 0.01 for treatment effect, repeated measures ANOVA).
(B) VDAC content in myotubes treated with LCM, represented as percent
control. (C) Change basal respiration in myotubes treated with LCM,
expressed as percent of control respiration (n = 12, ∗P < 0.01, ANOVA,
Bonferroni post-hoc). (D) ATP-related OCR/VDAC in myotubes treated with
LCM expressed as percent basal control (n = 12, ∗P < 0.05, ANOVA,
Bonferroni post-hoc test).
LCM-INDUCED CHANGES IN OXIDANT PRODUCTION
The ETC constitutively produces reactive oxygen species (ROS)
during activity and is the greatest source of oxidants in skele-
tal muscle (Turrens, 2003). It is therefore likely that changes in
ETC activity are reflected in alterations in ROS production. To
test our hypothesis that LCM treatment would alter the level
of oxidants, we examined general oxidant production, reactive
nitrogen species (RNS) production, and mitochondrial superox-
ide anion production in myotubes treated with LCM for 30min,
4, 6, and 24 h. DCF fluorescence measures overall cytosolic oxi-
dant activity. Cytosolic oxidants increased at 30min and 4 h
compared to control myotubes (Figure 4A). However, after 24 h
of LCM treatment, cytosolic oxidants decreased (Figure 4A).
DAF fluorescence, which measures RNS production, was unal-
tered by LCM treatments (Figure 4B). These data indicated that
RNS did not contribute to changes in overall cytosolic oxidant
activity, as measured by DCF fluorescence. We hypothesized
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FIGURE 2 | Protein content of electron transport chain complexes.
Samples were equal protein loaded, which was determined via SDS-PAGE
and staining with Simply Blue. Western blot membranes showed no
changes in protein content for mitochondrial complex I NDUFA9, complex
III subunit core I, complex IV subunit IV, and complex V, subunit α (n = 6).
FIGURE 3 | The effect of LCM treatment on cytochrome c oxidase
activity. (A) Cytochrome C absorbance decreases after a 2 h exposure to
LCM, indicating an increase in cytochrome c oxidase activity.
(B) Cytochrome oxidase activity defined by the rate of change in the linear
range permg protein. LCM treatment for 2 h increased activity to 144% of
control (n = 8, ∗P < 0.01, t-test).
that some of the changes in DCF fluorescence might originate
from the ETC. Using a CCD camera attached to a fluorescence
microscope, we tested our hypothesis by measuring changes to
the fluorescence intensity of mitochondrial superoxide indicator,
MitoSox, in myotubes treated with LCM, LCM combined with
mitochondrial-targeted antioxidant, SS31, and LCM combined
with general antioxidant, N-Acetylcysteine (NAC). We found that
after 2 h of LCM treatment, MitoSox fluorescence increased com-
pared to control myotubes (Figures 4C,D). Myotubes treated
for 2 h with LCM combined with mitochondrial antioxidant,
SS31, had reduced MitoSox fluorescence compared to myotubes
treated with LCM alone (Figure 4D). Myotubes treated with LCM
combined with NAC had no significant alteration in MitoSox
fluorescence (Figure 4D).
THE EFFECT OF LCM TREATMENT ON UCP3 CONTENT
The DCF results with 24 h of LCM treatment are consistent with
ETC uncoupling. UCP3 is the most abundant uncoupling protein
in skeletal muscle, and we speculated that its expression may be
elevated with prolonged LCM exposure as a protection against
FIGURE 4 | LCM treatment alters oxidant production. (A) DCFH
fluorescence, a measurement of cytosolic oxidant levels, was increased by
LCM treatment for 30min and 4 h, but reduced by 24 h of treatment,
represented as percent change (n = 10, ∗P < 0.05, ANOVA, Bonferroni
post-hoc). (B) Unaltered DAF fluorescence in myotubes treated with LCM
for 30min, 2, and 24 h, represented as percent change (n = 20,
non-significant, ANOVA, Bonferroni post-hoc). (C) Fluorescence images of
control myotubes (top panel) and LCM-treated myotubes (bottom panel)
treated with MitoSox. (D) 2h of LCM treatment increased MitoSox
fluorescence compared to control; 2 h of LCM treatment combined with
SS31 decreased Mitosox fluorescence compared to LCM-treated
myotubes; and 2 h of LCM treatment combined with NAC did not alter
MitoSox fluorescence significantly (n = 4, ∗P < 0.05, Bonferroni post-hoc).
LCM-induced oxidative damage by reducing ROS production
(Maclellan et al., 2005; Toime and Brand, 2010). We examined the
content of UCP3 via western blot and found that its expression
was unaffected by LCM treatment (Figure 5).
EFFECT OF LCM TREATMENT ON PROTEIN OXIDATION
LCM treatment caused a transient increase in ROS, poten-
tially leading to oxidized proteins that may affect ETC activity
(Figure 4).We isolatedmitochondria frommyotubes treated for 2
or 48 h with LCM. After 2 h of LCM treatment, 4-hydroxynonenal
(HNE) was elevated in the cytosolic fraction, and after 48 h,
HNE was elevated in both cytosolic and mitochondrial fractions
(Figure 6). These data indicate that LCM oxidizes both cytoso-
lic and mitochondrial proteins, which may result in alterations to
their functions.
DISCUSSION
Mitochondrial dysfunction has been reported in several models of
cancer cachexia; however, there have been conflicting data regard-
ing the nature of alterations to the ETC (Busquets et al., 2005;
Constantinou et al., 2011; Julienne et al., 2012; Khamoui and
Kim, 2012; Tzika et al., 2013). One primary feature of cachexia
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FIGURE 5 | The effect of LCM treatment on UCP3 content. The left panel
shows a representative western blot with anti-UCP3 in control and
LCM-treated myotubes. The right panel shows the quantification of
western blot represented as percent control (n = 6, t-test). 24 h of LCM
treatment does not alter UCP3 content.
is that the remaining muscle mass becomes easily fatigued, sug-
gesting possible ETC dysfunction. For example, alterations to
the ETC could promote fatigue through loss of ATP production,
increased production of ROS, or both (Roberts et al., 2013a,b).
Previous studies have found that excessive ROS oxidize myofib-
rillar proteins in skeletal muscle, and it is reasonable to hypoth-
esize that ROS may also contribute to cachectic fatigue in this
manner (Bruton et al., 2008; Reid, 2008; Prochniewicz et al.,
2008a,b; Fedorova et al., 2010). In this study, we used an in vitro
model of cancer cachexia to focus on the direct action of cancer-
conditioned media on mitochondrial function, protein content,
ROS production, and oxidative stress in skeletal muscle.
Our results show that LCM changed ETC activity in C2C12
myotubes in a time-dependent manner (Figure 1A). ETC activ-
ity was altered by LCM treatment. LCM exposure of 2 and
24 h lead to depressed basal respiration and ATP-related OCR
(Figures 1C,D). The altered ETC activity with longer treatment
times could have several possible explanations: less mitochondria
in LCM-treated cells, reduced content of mitochondrial com-
plexes, or increased ROS production. We tested protein content
of VDAC as a measurement of mitochondrial content and found
it unaffected by LCM treatment (Figure 1B). With this finding,
we used VDAC as a means of normalization in XF analyzer mea-
surements of OCR. We also measured the protein content of
ETC complexes I, III, IV, and V, and found that LCM treatment
did not alter expression (Figure 2). With content of mitochon-
dria and the complexes remaining intact, alterations to complex
activity became a candidate to explain our OCR results. Complex
IV, cytochrome c oxidase, is the last electron carrier of the ETC,
passing four electrons from reduced cytochrome c to molecular
oxygen to produce water. If complex IV activity is diminished,
it suggests that electron transport is slowed. We found that 2 h
of LCM treatment increased Complex IV activity, which seems
to contradict our hypothesis (Figure 3). However, Turrens found
that ETC-generated superoxide can reduce cytochrome c directly
FIGURE 6 | LCM treatment oxidizes proteins. The upper panel shows
western blot for anti-4HNE in cytosolic and mitochondrial myotube fractions
treated with LCM for 2 or 48 h, vs. control myotubes. The bottom panel
shows the quantification anti-4HNE western blots (n = 4, ∗P < 0.05,
ANOVA, Bonferroni post-hoc). LCM treatment for 2 and 48 h increased HNE
content in both cytosolic and mitochondrial portions of cell lysates.
leading to increased Complex IV activity while bypassing com-
plexes I and III (Turrens, 2003). In other words, the activity could
increase if more reduced cytochrome c substrate was present due
to an increase in superoxide production.
The complex IV activity data suggested the possibility that
LCM treatment caused an increase in ROS production. Although
normal physiological activity of the ETC constitutively produces
some ROS as electrons slip off of complexes I and III, exces-
sive oxidant production is known to cause oxidation damage to
proteins, lipids, and DNA (St-Pierre et al., 2002; Turrens, 2003).
We hypothesized that LCM treatment was inducing excessive oxi-
dant production, leading to oxidative stress in our model. LCM
treatment initially increased oxidant production, but by 24 h
after treatment, oxidants were depressed below control condi-
tions (Figure 4A). Lack of changes in DAF fluorescence elimi-
nated RNS contributions in our system (Figure 4B). Increased
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MitoSox fluorescence with LCM treatment implicated mito-
chondrial superoxide as a source for the initial rise in oxi-
dant production (Figure 4C). This hypothesis was supported
by additional experiments in which we showed a decrease in
MitoSox fluorescence when LCM treatment was combined with
mitochondrial targeting antioxidant, SS31, but not with gen-
eral antioxidant, NAC (Figures 4C,D) An increase in super-
oxide may also explain our increase in cytochrome c oxidase
activity.
Depressed oxidant production after 24 h of LCM treatment
suggests that uncoupling may occur in our model. Uncoupling
increases in response to elevated ROS production as a means of
reducing ROS and the potential damage they inflict (Maclellan
et al., 2005; Toime and Brand, 2010). Mitochondria are consid-
ered uncoupled when electrons move through the inner mito-
chondrial membrane without participating in ATP production.
Other studies on cachectic skeletal muscle have found both
increased and unchanged expression of uncoupling protein three
(UCP3), the main uncoupling protein in skeletal muscle (Vidal-
Puig et al., 1997; Constantinou et al., 2011; Julienne et al., 2012;
Antunes et al., 2014). We found no change in the expression of
UCP3 despite the depression in ROS production (Figure 5). With
UCP3 unchanged, we wondered if oxidative damage might affect
ETC activity, leading to a subsequent decrease in ETC-generated
ROS production over time.
We tested the effect of LCM treatment on oxidative stress. 4-
hydroxynonenal is a product of lipid peroxidation, and acts as
both a marker and inducer of oxidative stress. It is known to
aggregate and cause oxidative damage to DNA and proteins (Chen
andNiki, 2006).We tested for 4HNE-modified proteins in cytoso-
lic and mitochondrial fractions of myotube lysates via anti-4HNE
western blot. We found that LCM increased 4HNE modifications
to proteins in both fractions after 48 h (Figure 6). These data
show that LCM causes oxidative damage, perhaps affecting ETC
activity.
CONCLUSIONS
Our results show that skeletal muscle cells treated with LCM expe-
rience altered ETC activity, including reduced basal respiration
and reduced ATP-related OCR. LCM treatment initially induces
a burst of ROS production, some of which is mitochondrial
superoxide. Our 4HNE results show that LCM induced oxidative
damage. 4HNE itself can act as a mediator of oxidative stress, and
potentially creates a self-amplifying loop of oxidative stress. Both
ROS and 4HNE can damage DNA, proteins, transcription factors,
and lipids, resulting in widespread cellular damage. Future work
should focus on discovering which LCM-derived paracrine fac-
tors are the upstreammediators in mitochondrial ETC alterations
seen in cachexia.
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